New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
07:49 EDTADXSAdvaxis to conduct 4 cancer immunotherapy clinical trials with GRU Cancer Center
Advaxis announced it has expanded its relationship by entering into a master clinical trial agreement with GRU Cancer Center to conduct four Phase 1/2 clinical trials. The planned trials will further develop Advaxis' two lead immunotherapies: ADXS-HPV for cervical cancer and ADXS-cHER2 for breast cancer. The planned trials will further develop Advaxis' two lead immunotherapies: ADXS-HPV for cervical cancer and ADXS-cHER2 for breast cancer. The four clinical trials will be designed to assess: High dose, repeating cycles of ADXS-HPV in recurrent or refractory cervical cancer. ADXS-cHER2 in women with Her2/neu over-expressing breast cancer with measurable disease who have progressed after prior standard therapy. The optimal combination dose of ADXS-HPV and PD-1 antibody in patients with recurrent or refractory cervical cancer. ADXS-HPV prior to surgery in patients with surgically treatable cervical cancer.
News For ADXS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 28, 2015
08:11 EDTADXSAdvaxis announces two USPTO patents addressing ADXS-PSA, ADXS-HER2
Advaxis announced that the United States Patent and Trademark Office has granted U.S. Patent No. 9,012,141 with composition of matter claims covering the Advaxis product candidate, ADXS-PSA, and U.S. Patent No. 9,017,660 with methods of use claims covering the Advaxis product candidate, ADXS-HER2. The first patent, which will expire on November 26, 2028, covers constructs related to ADXS-PSA, Advaxis's Lm-LLO immunotherapy candidate being developed to address prostate cancer. Specifically, the patent provides composition of matter protection for a recombinant Listeria strain encoded with recombinant fusion peptide of KLK3 peptide linked to non-KLK3 peptide. The second patent, which will expire on January 14, 2031, covers methods of use for ADXS-HER2, Advaxis's Lm-LLO immunotherapy candidate designed to target HER2 receptor expressing cancers. The patent provides method of use protection in treating HER2/Neu expressing tumors, particularly osteosarcoma, in non-human animals and companion dogs.
April 22, 2015
11:52 EDTADXSAdvaxis management to meet with Jefferies
Meeting to be held in New York on April 28 hosted by Jefferies.
April 21, 2015
13:01 EDTADXSAdvaxis presents Lm-LLO cancer immunotherapy data at AACR meeting
Advaxis announced the data of one clinical and two preclinical studies highlighting the survival outcomes and anti-tumor effects of its proprietary Lm-LLO cancer immunotherapy technology at the American Association for Cancer Research Annual Meeting 2015, held April 18 22 in Philadelphia, Pennsylvania. On Tuesday, April 21, Samir Khleif, M.D., Director of the State of Georgia Cancer Center, Georgia Regents University Cancer Center, presented on a preclinical study evaluating the therapeutic potential of ADXS-HPV in combination with anti-OX40 and anti-GITR antibodies. The data demonstrated that the combination of therapies led to significant inhibition of tumor growth and prolonged survival in tumor bearing mice. Complete regression of established tumors occurred in 40% and 60% of animals treated with ADXS-HPV in combination with anti-OX40 and anti-GITR antibodies, respectively. On Monday, April 20, Nicola J. Mason, BVetMed, Ph.D., DACVIM, Assistant Professor of Medicine, University of Pennsylvania's School of Veterinary Medicine, presented preliminary data from an ongoing Phase 1 clinical study of 10 companion dogs with osteosarcoma. The data suggests that ADXS-HER2 in combination with palliative radiation delayed tumor progression and prolonged overall survival in pet dogs with spontaneous osteosarcoma that were not candidates for primary tumor removal. Repeat doses of ADXS-HER2 were well tolerated with no systemic or cardiac toxicity. Additionally, the combination treatment was found to maintain or improve limb function and quality of life over the study period. Five of the treated dogs remain alive, with a median survival, to date, of all 10 study dogs reported at 285 days, which compares favorably to historical median survival time of 136 days in dogs treated with palliative radiation only.
April 20, 2015
07:20 EDTADXSAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
April 17, 2015
17:03 EDTADXSAdvaxis files to sell $200M of common stock

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use